Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07429266 · ClinicalTrials.gov registry record · Phase 3
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
A Phase 3 study, sponsored by Ono Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT07429266 is a Phase 3 study that is actively recruiting participants, run by Ono Pharmaceutical Co.. The registered enrollment target is 250 participants.
The verdict
NCT07429266, a Phase 3 study, is actively recruiting participants, sponsored by Ono Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
Interventions
- DRUG Placebo
- DRUG Sapablursen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-05-25 |
| Est. Completion | 2031-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07429266
The ClinicalTrials.gov registry entry for NCT07429266 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07429266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07429266 about?
NCT07429266 is a clinical study titled "INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)". The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term exte...
What is the current status of trial NCT07429266?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2026-05-25. Estimated completion is 2031-01.
What interventions are being tested in trial NCT07429266?
The interventions under investigation include: Placebo (DRUG), Sapablursen (DRUG).
Who is sponsoring clinical trial NCT07429266?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.